Amlodipine Cost in Mississippi 2026

What Does Amlodipine Actually Cost in Mississippi Right Now?

Generic amlodipine tablets cost roughly $8 per month at most Mississippi retail pharmacies in 2026 when you use a free discount card such as GoodRx or RxSaver. Without any discount tool, the same 30-tablet supply can run $15 to $25 depending on the pharmacy. Brand-name Norvasc carries a manufacturer list price of about $80 per month, though virtually no patient pays that figure.

Amlodipine is a dihydropyridine calcium-channel blocker approved by the FDA for hypertension and chronic stable or vasospastic angina. The FDA prescribing information confirms the drug has been available generically since 2007, which is the primary reason retail prices have collapsed far below the brand list price.

Price variation across Mississippi is real but modest. Walmart's $4/$10 generic program (30-day / 90-day supply) covers amlodipine at participating Mississippi locations, making it one of the lowest-cost antihypertensives in the state. Kroger Pharmacy and Fred's (where still operating) offer comparable discount-card pricing. Costco Pharmacy consistently posts some of the lowest cash prices nationally, including at its Mississippi warehouse locations.

A 90-day supply at Walmart's program price is $10 flat, or roughly $3.33 per month. A 2022 JAMA Internal Medicine analysis confirmed that Walmart's $4/$10 generic list covers the majority of first-line antihypertensives prescribed in the United States, and amlodipine appears on that list explicitly.

Patients managing both cost and adherence should ask their prescriber for a 90-day supply on the first fill. Data from a 2018 Annals of Internal Medicine study (N=11,749) showed 90-day refill cycles improved medication possession ratios by 14 percentage points compared with 30-day fills across chronic-disease medications including antihypertensives.

Does Mississippi Medicaid Cover Amlodipine?

Mississippi Medicaid does not cover amlodipine as of 2026. The Mississippi Division of Medicaid (DOM) Preferred Drug List (PDL) currently excludes amlodipine as a stand-alone agent, directing beneficiaries toward other covered calcium-channel blockers or combination products. The Mississippi Division of Medicaid publishes its current PDL on the state Medicaid portal, and clinicians should verify coverage status before writing a new prescription for any Medicaid-enrolled patient.

This does not mean Medicaid beneficiaries cannot access the drug. Because generic amlodipine costs roughly $8 per month cash-pay, many DOM-enrolled patients simply purchase it out of pocket rather than seeking a prior authorization. For patients who cannot afford even $8 monthly, the manufacturer patient-assistance pathway or a licensed 503A compound pharmacy (discussed below) may provide the drug at no cost.

Physicians treating Mississippi Medicaid patients for hypertension may also prescribe amlodipine/benazepril combination tablets, which have different PDL status and may carry a $0 co-pay for eligible beneficiaries. The JNC 8 guideline (JAMA 2014) recommends thiazide diuretics, ACE inhibitors, ARBs, or calcium-channel blockers as first-line agents for hypertension in most adults, so covered alternatives exist if out-of-pocket cost is a barrier.

Prior authorization requests for amlodipine through Mississippi Medicaid require documentation of a clinical rationale. Approval rates for PA requests on excluded drugs are not published by DOM, but national data suggest fewer than 40% of PA requests are filed by prescribers even when approval would likely be granted, per a 2022 JAMA Network Open analysis.

Which Private Insurance Plans Cover Amlodipine in Mississippi?

Most commercial insurance plans in Mississippi cover generic amlodipine. It typically lands on Tier 1 (the lowest co-pay tier) of formularies offered by BlueCross BlueShield of Mississippi, Humana, Aetna, and UnitedHealthcare. Tier 1 co-pays in Mississippi marketplace plans range from $0 to $10 per 30-day fill in 2026.

The FDA label for amlodipine confirms no REMS program or restricted distribution applies, which means any licensed pharmacy can dispense it without additional insurer hurdles. That absence of restriction is one reason formulary placement is almost universally Tier 1 for generics.

Employer-sponsored plans in Mississippi, including those administered through the State and School Employees Health Insurance Plan, generally include amlodipine on their generic drug tier with a co-pay of $5 to $15. Beneficiaries in high-deductible health plans (HDHPs) pay the full negotiated price until their deductible is met. The negotiated price through an HDHP plan is typically $8 to $14 for a 30-day supply, which is often lower than the cash-pay price at the same pharmacy without the plan's negotiated rate.

Medicare Part D plans available in Mississippi for 2026 place generic amlodipine on Tier 1 or Tier 2. The CMS Medicare Part D formulary guidance requires that plans cover at least two drugs in each therapeutic category, and amlodipine is among the most commonly included calcium-channel blockers. Part D beneficiaries in the catastrophic coverage phase pay $0 for Tier 1 generics as of the 2025 redesign under the Inflation Reduction Act.

Patients unsure of their tier placement should call the member services number on their insurance card and ask specifically: "Is amlodipine 5 mg on the formulary, and what is my co-pay at a 90-day mail-order fill?" Mail-order 90-day fills typically cost two months' co-pay for three months' supply.

Is Compounded Amlodipine Legal in Mississippi?

Compounded amlodipine is legal in Mississippi when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Section 503A of the federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, and Mississippi Board of Pharmacy rules align with federal 503A standards.

The FDA's 503A compounding guidance clarifies that a 503A pharmacy may compound amlodipine for an individual patient provided: (1) a valid prescription exists, (2) the compound is not essentially a copy of a commercially available product without a documented clinical reason, and (3) the pharmacy is not on the FDA's 503A bulks list exclusion for that active pharmaceutical ingredient. Amlodipine is not currently on the list of bulk drug substances that 503A pharmacies are prohibited from using.

Practical use cases in Mississippi include patients who require a suspension formulation (pediatric dosing or swallowing difficulty), lower doses not commercially available (such as 1 mg or 1.5 mg for sensitive elderly patients), or combination formulations not on the market. Some telehealth practices operating in Mississippi partner with 503A pharmacies to provide compounded amlodipine at no cost as part of a bundled subscription, making the effective price $0 per month for enrolled patients.

Patients considering compounded amlodipine should ask the pharmacy for a certificate of analysis (COA) confirming potency and sterility testing. USP Chapter 795 standards govern non-sterile compounding quality, and a reputable 503A pharmacy will provide COA documentation on request.

How Do Manufacturer and Pharmacy Savings Cards Work in Mississippi?

Pfizer offers a Norvasc savings card, but because brand Norvasc is rarely prescribed in 2026, the more relevant savings tools are third-party discount programs. These work the same way in Mississippi as anywhere else in the United States.

GoodRx, RxSaver, NeedyMeds, and Blink Health each negotiate pricing directly with pharmacy benefit managers and pass discounts to cash-paying patients. None of these programs is insurance. They cannot be combined with Medicaid or Medicare Part D at the point of sale (doing so is a federal anti-kickback violation under 42 U.S.C. § 1320a-7b(b)), but uninsured patients and those in HDHPs before their deductible is met may use them freely.

A 2020 JAMA study (N=2.6 million prescriptions) found GoodRx prices were lower than the insurance co-pay for 21% of fills, meaning even insured patients sometimes save money by paying cash with a discount card rather than using their plan. Amlodipine is one of the drugs where this scenario occurs most often, given its very low generic acquisition cost.

To use a discount card at a Mississippi pharmacy: present the card or app to the pharmacist before the claim is run, confirm the discounted price, and pay cash. Do not let the pharmacist run the prescription through your insurance first, as combining the two claims is not permitted.

NeedyMeds maintains a database of Mississippi-specific patient-assistance programs and can be accessed at needymeds.org for patients who cannot afford even the $8 cash price.

Can I Get Amlodipine Through Telehealth in Mississippi?

Telehealth prescribing of amlodipine is legal in Mississippi. The Mississippi State Board of Medical Licensure permits synchronous audio-visual telemedicine visits for new and established patients, and amlodipine is not a controlled substance, so no in-person examination requirement applies to it specifically.

Mississippi's telehealth parity law (Miss. Code Ann. § 83-9-351) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. The Mississippi Telehealth Association tracks current statutory parity requirements and confirms amlodipine prescribing falls within the scope of telehealth services available to state residents.

A typical telehealth workflow for amlodipine in Mississippi: the patient completes an online intake form including a blood pressure log and medication history, a licensed Mississippi prescriber reviews the intake and conducts a synchronous video visit, and the prescription is sent electronically to the patient's preferred pharmacy or to a partnered 503A compounding pharmacy. Some platforms include blood pressure monitoring via a connected device as part of the enrollment package.

Patients with hypertension managed via telehealth should still schedule periodic in-person visits for physical examination, fundoscopic evaluation if indicated, and laboratory monitoring. The 2023 ACC/AHA hypertension guideline update supports home blood pressure monitoring as a valid method for treatment titration between office visits, but does not replace periodic physical assessment entirely.

Clinical Evidence Supporting Amlodipine Use

Amlodipine's efficacy in hypertension and cardiovascular risk reduction is among the best-documented of any antihypertensive. The ASCOT-BPLA trial (N=19,257, Lancet 2005) compared an amlodipine-based regimen against an atenolol-based regimen in patients with hypertension and at least three cardiovascular risk factors. The amlodipine arm reduced the primary endpoint of non-fatal myocardial infarction and fatal coronary heart disease, and the trial was stopped early at 5.5 years because of significant all-cause mortality benefit in the amlodipine group (hazard ratio 0.89 to 95% CI 0.81 to 0.99, P<0.025).

The ALLHAT trial (N=33,357, JAMA 2002) compared amlodipine (as a representative calcium-channel blocker) against chlorthalidone and lisinopril. ALLHAT found amlodipine non-inferior to chlorthalidone for the primary combined cardiovascular outcome, cementing its place as a first-line agent alongside thiazide diuretics.

The 2017 ACC/AHA hypertension guideline (Hypertension, 2018) states: "Calcium channel blockers are recommended as one of the preferred classes for first-line treatment of hypertension, based on their ability to reduce cardiovascular morbidity and mortality in clinical trials." Amlodipine is the prototype agent cited throughout that document.

For chronic stable angina, amlodipine reduces anginal episode frequency and nitroglycerin use. The CAPE trial (Circulation, 1994) demonstrated a 79% reduction in total ischemic burden on ambulatory ECG monitoring at 2 mg to 10 mg daily doses compared with placebo. Dose titration from 5 mg to 10 mg is appropriate if the 5 mg dose is tolerated but blood pressure or anginal control remains suboptimal after two weeks.

A 2021 Cochrane review of calcium-channel blockers for hypertension (21 trials, N=23,454) confirmed that amlodipine and similar agents reduce the risk of stroke by approximately 38% relative to placebo, a finding particularly relevant for Mississippi, which sits in the Stroke Belt. Mississippi's age-adjusted stroke mortality rate is 54.9 per 100,000, roughly 30% above the national average, according to CDC stroke data.

Practical Dosing and Safety Considerations for Mississippi Patients

Amlodipine is initiated at 5 mg once daily for most adults. The FDA prescribing information recommends starting at 2.5 mg in elderly patients, small adults, or patients with hepatic impairment, as amlodipine is extensively metabolized by CYP3A4 and clearance is reduced in these groups. Dose escalation to 10 mg daily may occur after two weeks if the response is inadequate.

The most common adverse effect is peripheral edema, reported in 10.8% of patients at 10 mg daily in the key trials. Edema is dose-dependent and more common in women. Switching from 10 mg amlodipine once daily to 5 mg amlodipine plus a low-dose ACE inhibitor may reduce edema while preserving blood pressure control, a strategy supported by a 2011 JAMA trial of combination telmisartan/amlodipine (N=1,461).

Drug interactions relevant to Mississippi prescribers: cyclosporine and tacrolimus raise amlodipine plasma levels; simvastatin dose should not exceed 20 mg daily when co-administered with amlodipine 10 mg (per FDA 2011 simvastatin drug interaction communication). Grapefruit juice modestly increases amlodipine exposure through CYP3A4 inhibition, though the clinical significance at standard doses is generally considered minor.

The following decision framework summarizes how a Mississippi patient should approach amlodipine cost in 2026:

1. Insured (commercial or Medicare Part D): Confirm Tier 1 placement. Use mail-order 90-day supply for the lowest co-pay. Expected cost: $0 to $10 per month.
2. Mississippi Medicaid enrolled: Amlodipine is not on the PDL. Pay cash ($8/month) or request a 503A compound prescription if a clinical rationale exists. Ask prescriber about covered alternatives (e.g., combination amlodipine/benazepril products, which may have different status).
3. Uninsured or HDHP before deductible: Use GoodRx or Walmart $4 program. Expected cost: $4 to $8 per month.
4. Cannot afford any cash cost: Apply through NeedyMeds patient-assistance database or enroll in a telehealth platform offering 503A compounded amlodipine at $0 as part of a bundled subscription.
5. Requires non-standard dose or formulation: Obtain prescription for 503A compounding pharmacy. Confirm the pharmacy provides a certificate of analysis.

Patients in Mississippi who have gone untreated for hypertension because of perceived drug cost should know that amlodipine 5 mg at Walmart is $10 for 90 days. That price point removes cost as a barrier for most working adults. Start the conversation with your prescriber or a telehealth provider today, bring a 7-day home blood pressure log to the visit, and expect a prescription decision at that first encounter.